iBio (IBIO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on iBio (IBIO) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.05 of bullish evidence against -0.39 bearish.

iBio last closed at $0.87, -5.43% on the session.

Against the IVW growth benchmark the position is -6.23% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

20 graded predictions for IBIO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks iBio in the 18th percentile on return on equity, where 100 is best.

iBio is classified under Health Care / Biotechnology, with a market capitalisation of $59.16M.

StockMap tracks iBio as the 304th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite iBio ranks 327th of 381 in the group, against a group median of -0.08.